Wednesday, May 25, 2016

BRIEF-Ablynx to present a post-hoc analysis of the PHASE II TITAN study with caplacizumab

* Ablynx to present a post-hoc analysis of the Phase II

TITAN study with caplacizumab in acquired TTP patients at the

21st congress of the European hematology association

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)